Luuk Gras
YOU?
Author Swipe
View article: Transplant conditioning intensity (TCI) score predicts allo-HCT outcomes in patients with myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT
Transplant conditioning intensity (TCI) score predicts allo-HCT outcomes in patients with myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT Open
Outcomes in myelofibrosis (MF) patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) appear unaffected by the intensity of the preparative regimen, defined traditionally as myeloablative (MAC) or reduced intensity co…
View article: Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia - a Study on Behalf of the Chronic Malignancies Working Party of the EBMT
Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia - a Study on Behalf of the Chronic Malignancies Working Party of the EBMT Open
Introduction T-cell prolymphocytic leukemia is a rare subtype of mature T-cell lymphoma, associated with poor outcomes. The standard approach is to bring eligible patients to allogeneic hematopoietic cell transplantation (allo-HCT) in the …
View article: Global characteristics and outcomes of autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma: A study of the worldwide network for blood and marrow transplantation (<scp>WBMT</scp>)
Global characteristics and outcomes of autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma: A study of the worldwide network for blood and marrow transplantation (<span>WBMT</span>) Open
Autologous hematopoietic cell transplantation (AHCT) is a commonly used treatment in multiple myeloma (MM). However, real‐world global demographic and outcome data are scarce. We collected data on baseline characteristics and outcomes from…
View article: Mismatched related donor allogeneic haematopoietic cell transplantation compared to other donor types for Ph+ chronic myeloid leukaemia: A retrospective analysis from the Chronic Malignancies Working Party of the EBMT
Mismatched related donor allogeneic haematopoietic cell transplantation compared to other donor types for Ph+ chronic myeloid leukaemia: A retrospective analysis from the Chronic Malignancies Working Party of the EBMT Open
Summary Allogeneic haematopoietic cell transplantation (allo‐HCT) remains an option for tyrosine kinase inhibitor‐resistant chronic myeloid leukaemia (CML) in first chronic phase (CP1) and high‐risk patients with advanced disease phases. I…
View article: Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation Open
There is little long-term outcome data on the efficacy of autologous hematopoietic stem cell transplantation (ASCT) in light chain deposition disease (LCDD). We identified 51 LCDD patients in the EBMT registry who had undergone upfront ASC…
View article: Autologous hematopoietic cell transplantation for T-cell prolymphocytic leukemia: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
Autologous hematopoietic cell transplantation for T-cell prolymphocytic leukemia: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT Open
Not available.
View article: Early liver complications after allogeneic haematopoietic stem cell transplantation in patients with myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of the <scp>EBMT</scp>
Early liver complications after allogeneic haematopoietic stem cell transplantation in patients with myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of the <span>EBMT</span> Open
peer reviewed
View article: Outcomes of <scp>CMML</scp> patients undergoing <scp>allo‐HCT</scp> are significantly worse compared to <scp>MDS</scp>—a study of the <scp>CMWP</scp> of the <scp>EBMT</scp>
Outcomes of <span>CMML</span> patients undergoing <span>allo‐HCT</span> are significantly worse compared to <span>MDS</span>—a study of the <span>CMWP</span> of the <span>EBMT</span> Open
Although CMML since long has been separated from MDS, many studies continue to evaluate the outcomes of both diseases after hematopoietic cell transplantation (allo‐HCT) together. Data evaluating outcomes of a large CMML cohort after allo‐…
View article: Sequential vs myeloablative vs reduced intensity conditioning for patients with myelodysplastic syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: a retrospective study by the chronic malignancies working party of the EBMT
Sequential vs myeloablative vs reduced intensity conditioning for patients with myelodysplastic syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: a retrospective study by the chronic malignancies working party of the EBMT Open
View article: A Randomized Controlled Trial to Study the Transmission of SARS-CoV-2 and Other Respiratory Viruses During Indoor Clubbing Events (ANRS0066s ITOC Study)
A Randomized Controlled Trial to Study the Transmission of SARS-CoV-2 and Other Respiratory Viruses During Indoor Clubbing Events (ANRS0066s ITOC Study) Open
Background In the context of the circulation of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.617.2 (Delta) variant, vaccination re-authorized mass indoor gatherings. The “Indoor Transmission of coronavirus disease 2…
View article: Graft-versus-Host Disease Prophylaxis with Post- Transplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT)
Graft-versus-Host Disease Prophylaxis with Post- Transplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT) Open
View article: Sequential vs Myeloablative vs Reduced Intensity Conditioning for Patients with Myelodysplastic Syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: A Retrospective Study by the Chronic Malignancies Working Party of the EBMT
Sequential vs Myeloablative vs Reduced Intensity Conditioning for Patients with Myelodysplastic Syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: A Retrospective Study by the Chronic Malignancies Working Party of the EBMT Open
The optimal conditioning for patients with higher risk MDS receiving potentially curative allogeneic haematopoietic stem cell transplant(allo-HCT) remains to be defined. This is particularly the case for patients with excess of blasts at t…
View article: Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients—The DIADEM study from the chronic malignancies working party of the EBMT
Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients—The DIADEM study from the chronic malignancies working party of the EBMT Open
View article: Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation Open
Allogeneic hematopoietic cell transplant (allo‐HCT) provides the only potential route to long‐term remission in patients diagnosed with blast phase transformation of myeloproliferative neoplasm (BP‐MPN). We report on a large, retrospective…
View article: Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience
Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience Open
International audience
View article: Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the <scp>EBMT</scp>
Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the <span>EBMT</span> Open
Following the introduction of tyrosine kinase inhibitors (TKI), the number of patients undergoing allogeneic hematopoietic cell transplantation (allo‐HCT) for chronic phase (CP) chronic myeloid leukemia (CML) has dramatically decreased. Im…
View article: Correction: Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT
Correction: Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT Open
View article: Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT
Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT Open
View article: Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT
Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT Open
Allogeneic hematopoietic cell transplantation (allo-HCT) is the only curative treatment for patients with myeloid/lymphoid neoplasm (MLN) with FGFR1 rearrangement, but data on overall results are limited. We report on the largest series of…
View article: Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT
Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT Open
View article: Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of <scp>EBMT</scp> and the Spanish Myelofibrosis Registry
Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of <span>EBMT</span> and the Spanish Myelofibrosis Registry Open
Allogeneic hematopoietic cell transplantation (allo‐HCT) is increasingly used in older myelofibrosis (MF) patients, but its risk/benefit ratio compared to non‐transplant approaches has not been evaluated in this population. We analyzed the…
View article: Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study
Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study Open
CSF biomarkers, including total-tau, neurofilament light chain (NfL) and amyloid-β, are increasingly being used to define and stage Alzheimer’s disease. These biomarkers can be measured more quickly and less invasively in plasma and may pr…
View article: Trends in setpoint plasma HIV-1 concentration and CD4 cell count before and after introduction of effective antiretroviral treatment in the ATHENA national observational cohort
Trends in setpoint plasma HIV-1 concentration and CD4 cell count before and after introduction of effective antiretroviral treatment in the ATHENA national observational cohort Open
De concentratie van HIV (humaan immunodeficiëntie virus) in bloed 6-12 maanden na infectie, de zogenaamde setpoint virale load, is een voorspeller voor het verdere (onbehandelde) ziektebeloop van HIV infectie. Luuk Gras beschrijft in een a…
View article: Determinants of Restoration of CD4 and CD8 Cell Counts and Their Ratio in HIV-1–Positive Individuals With Sustained Virological Suppression on Antiretroviral Therapy
Determinants of Restoration of CD4 and CD8 Cell Counts and Their Ratio in HIV-1–Positive Individuals With Sustained Virological Suppression on Antiretroviral Therapy Open
Background: An increasing number of HIV-positive individuals now start antiretroviral therapy (ART) with high CD4 cell counts. We investigated whether this makes restoration of CD4 and CD8 cell counts and the CD4:CD8 ratio during virologic…
View article: Temporal association patterns and dynamics of amyloid-β and tau in Alzheimer’s disease
Temporal association patterns and dynamics of amyloid-β and tau in Alzheimer’s disease Open
View article: Reference curves for <scp>CD</scp>4 T‐cell count response to combination antiretroviral therapy in <scp>HIV</scp>‐1‐infected treatment‐naïve patients
Reference curves for <span>CD</span>4 T‐cell count response to combination antiretroviral therapy in <span>HIV</span>‐1‐infected treatment‐naïve patients Open
Objectives The aim of this work was to provide a reference for the CD 4 T‐cell count response in the early months after the initiation of combination antiretroviral therapy ( cART ) in HIV ‐1‐infected patients. Methods All patients in the …
View article: From clinical sample to complete genome: Comparing methods for the extraction of HIV-1 RNA for high-throughput deep sequencing
From clinical sample to complete genome: Comparing methods for the extraction of HIV-1 RNA for high-throughput deep sequencing Open
View article: Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment‐naïve <scp>HIV</scp>‐1‐infected patients in the Dutch <scp>AIDS</scp> Therapy Evaluation in the Netherlands (<scp>ATHENA</scp>) cohort
Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment‐naïve <span>HIV</span>‐1‐infected patients in the Dutch <span>AIDS</span> Therapy Evaluation in the Netherlands (<span>ATHENA</span>) cohort Open
Objectives Lamivudine (3 TC ) and emtricitabine ( FTC ) are considered interchangeable in recommended tenofovir disoproxil‐fumarate ( TDF )‐containing combination antiretroviral therapies ( cART s). This statement of equivalence has not be…
View article: Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study
Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study Open
View article: Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study
Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study Open
Background. Although human immunodeficiency virus (HIV)-positive persons on antiretroviral therapy (ART) frequently have chronic liver enzyme elevation (cLEE), the underlying cause is often unclear. Methods. Data Collection on Adverse Even…